Apotex Health Corp.
$1,300,000,080.00
54,166,670.00 Common Shares at $24.00
Initial Public Offering - Closed - Tuesday, June 16, 2026
Company Description
Apotex is a Canadian-based global health company that improves everyday access to affordable, innovative medicines and health products for millions of people around the world, with a broad portfolio of generic, branded and biosimilar pharmaceuticals, as well as branded consumer health and wellness products.
| Address: |
150 Signet Dr. North-York, Ontario, M9L 1T9 Canada |
|---|---|
| Phone Number: | 800-268-4623 |
| Fax Number: | |
| Website: |
| Industry: | Pharmaceuticals |
|---|---|
| Closing Date: | Tuesday, June 16, 2026 |
| 1st Day of Trading: | Tuesday, June 16, 2026 |
| Primary Symbol: | APTX |
| Exchange: | Venture |
Proceeds
The net proceeds of the offering will be used to repay indebtedness owing under the credit facilities. The specific indebtedness to be repaid under the credit facilities is the indebtedness outstanding under the Pari Passu term loan. The Company will not receive any proceeds from the secondary offering.
| Gross Proceeds: | US $1,300,000,080.00 |
|---|---|
| Underwrting Fees: | US $25,800,000.00 |
| Expense Offering: | US $0.00 |
| Net Proceeds: | US $1,274,200,080.00 |
| Lead Underwriter: | RBC Dominion Securities Inc. |
|---|---|
| Other Underwriter(s): |
CIBC World Markets Inc. BMO Nesbitt Burns Inc. TD Securities Inc. Scotia Capital Inc. National Bank Financial Inc. Desjardins Securities Inc. Raymond James Ltd. Paradigm Capital Inc. Canaccord Genuity Corp. Stifel Nicolaus Canada Inc. Bloom Burton & Co. Ltd Jefferies Securities Inc. MUFG Securities Canada, Ltd ATB Capital Markets Inc. |
Performance
| 1 day | 1 week | 1 month | 6 months | Inception | |
|---|---|---|---|---|---|
| Recent Performance | -0.03 % | -4.62 % | 6.93 % | 49.75 % | |
| Post IPO Performance | 12.50 % | 27.33 % |
The content of this page is transmitted strictly for informational purposes. Investments must be selected in accordance with the investor's respective objectives. Desjardins Online Brokerage does not issue any recommendations or endorsements concerning any particular product, its potential value or appropriateness, or any specific strategy. It is highly recommended to read the prospectus before making any type of investment.